Inverse vaccination with islet autoantigens to halt progression of autoimmune diabetes

Drug Development Research

Volumn 72, Issue 8, 2011, Pages 788-804

  Hinke, Simon A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cells; LADA; negative immunization; T cells; type 1 diabetes

Indexed keywords

ALTERED PEPTIDE LIGAND INSULIN; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 60 DERIVED PEPTIDE; INSULIN; NBI 6024; PLACEBO; PROINSULIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; BETA CHAIN; DRUG EFFICACY; DRUG FORMULARY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 83655182406     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20488     Document Type: Review

References (113)

1. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR,. 1999. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Automimmun 12: 121-129. (Pubitemid 29130589)
2. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A,. 2005. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19: 238-246. (Pubitemid 40910206)
3. Agardh CD, Lynch KF, Palmer M, Link K, Lernmark A,. 2009. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52: 1363-1368.
4. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A,. 2001. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 107: 173-180. (Pubitemid 32096833)
5. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, et al. 2002. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 51: 2126-2134. (Pubitemid 34729017)
6. Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, et al. 2006. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 63: 59-69.
7. Assan R, Feutren G, Debray-Sachs M, Quiniou-Debrie MC, Laborie C, Thomas G, Chatenoud L, Bach JF,. 1985. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1: 67-71. (Pubitemid 15189820)
8. Atkinson MA, Holmes LA, Scharp DW, Lacy PE, Maclaren NK,. 1991. No evidence for serological autoimmunity to islet cell heat shock proteins in insulin dependent diabetes. J Clin Invest 87: 721-724.
9. Atkinson MA, Leiter EH,. 1999. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5: 601-604. (Pubitemid 29289413)
10. Atkinson MA, Maclaren NK, Luchetta R,. 1990. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39: 933-937.
11. Avesani L, Bortesi L, Santi L, Falorni A, Pezzotti M,. 2010. Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: where are we? Expert Rev Vaccines 9: 957-969.
12. Axelsson S, Hjorth M, Akerman L, Ludvigsson J, Casas R,. 2010. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65). Diabetes Metab Res Rev 26: 559-568.
13. Bekris LM, Jensen RA, Lagerquist E, Hall TR, Agardh CD, Cilio CM, Lethagen AL, Lernmark A, Robertson JA, Hampe CS,. 2007. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabetic Med 24: 521-526. (Pubitemid 46669313)
14. + T cells that suppress adoptive transfer of diabetes. J Automimmun 7: 655-663. (Pubitemid 24327697)
15. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lindblad M, Mayer A, Czerkinsky C, Holmgren J, et al. 1997. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 94: 4610-4614. (Pubitemid 27194290)
16. Bottazzo GF, Florin-Christensen A, Doniach D,. 1974. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2: 1279-1283.
17. Braun M, Wendt A, Birnir B, Broman J, Eliasson L, Galvanovskis J, Gromada J, Mulder H, Rorsman P,. 2004. Regulated exocytosis of GABA-containing synaptic-like microvesicles in pancreatic beta-cells. J Gen Physiol 123: 191-204. (Pubitemid 38282970)
18. Bresson D, von Herrath M,. 2007. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmunity Rev 6: 315-322. (Pubitemid 46507996)
19. Bresson D, von Herrath M,. 2009. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside. Diabetes care 32: 1753-1768.
20. Brice NL, Varadi A, Ashcroft SJ, Molnar E,. 2002. Metabotropic glutamate and GABA(B) receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells. Diabetologia 45: 242-252. (Pubitemid 34208387)
21. Brudzynski K, Cunningham IA, Martinez V,. 1995. A family of hsp60-related proteins in pancreatic beta cells of non-obese diabetic (NOD) mice. J Automimmun 8: 859-874. (Pubitemid 26046549)
22. CDC. 2008. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: Centers for Disease Control and Prevention. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
23. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, et al. 2000. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356: 545-549. (Pubitemid 30611859)
24. Chase MW,. 1946. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc Soc Exp Biol Med 61: 257-259.
25. Cheramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R,. 2010. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response. Clin Immunol 137: 31-40.
26. Chessler SD, Lernmark A,. 2000. Alternative splicing of GAD67 results in the synthesis of a third form of glutamic-acid decarboxylase in human islets and other non-neural tissues. J Biol Chem 275: 5188-5192. (Pubitemid 30108922)
27. r autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J Clin Invest 92: 240-248. (Pubitemid 23209002)
28. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL,. 2005. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54: S97-107. (Pubitemid 43343337)
29. Daniel D, Wegmann DR,. 1996. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 93: 956-960. (Pubitemid 26041202)
30. DPT-1. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346: 1685-1691.
31. + T-cell clones specific for pancreatic islet autoantigens. J Automimmun 36: 47-55.
32. Dudani AK, Gupta RS,. 1989. Immunological characterization of a human homolog of the 65-kilodalton mycobacterial antigen. Infection Immun 57: 2786-2793. (Pubitemid 19212613)
33. Eldor R, Kassem S, Raz I,. 2009. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev 25: 316-320.
34. Elias D, Avron A, Tamir M, Raz I,. 2006. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann NY Acad Sci 1079: 340-344. (Pubitemid 44968744)
35. Elias D, Cohen IR,. 1994. Peptide therapy for diabetes in NOD mice. Lancet 343: 704-706. (Pubitemid 24087851)
36. Elias D, Cohen IR,. 1995. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes 44: 1132-1138.
37. Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR,. 1990. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci USA 87: 1576-1580.
38. Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Konen-Waisman S, Cohen IR,. 1997. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 46: 758-764. (Pubitemid 27188251)
39. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR,. 1991. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 88: 3088-3091. (Pubitemid 21916564)
40. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC,. 2005. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48: 2206-2212. (Pubitemid 41618908)
41. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J, Colman PG, Harrison LC,. 2011. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60: 1237-1245.
42. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG,. 1998. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 41: 536-541. (Pubitemid 28206823)
43. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS,. 2010. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes care 33: 826-832.
44. Grose S,. 2007. Australia set to test insulin "vaccine" for juvenile diabetes. Nat Med 13: 111.
45. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, Couper JJ, Colman PG,. 2004. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27: 2348-2355. (Pubitemid 39281384)
46. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA,. 2005. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-1769. (Pubitemid 40770766)
47. Hinke SA,. 2008. Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. Current opinion in molecular therapeutics 10: 516-525.
48. regs) with minimal loss of in vivo functional activity. Science translational medicine 3: 83ra41.
49. + cells in type 1 diabetic patients. Clinical immunology 138: 117-126.
50. Hutchings P, Cooke A,. 1998. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Automimmun 11: 127-130. (Pubitemid 28273008)
51. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO,. 2007. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 23: 269-275. (Pubitemid 46851467)
52. Huurman VA, van der Meide PE, Duinkerken G, Willemen S, Cohen IR, Elias D, Roep BO,. 2008. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 152: 488-497. (Pubitemid 351661507)
53. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M, et al. 1993. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92: 2313-2322. (Pubitemid 23333537)
54. Jindal S, Dudani AK, Singh B, Harley CB, Gupta RS,. 1989. Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol 9: 2279-2283. (Pubitemid 19117837)
55. Johnson MC, Wang B, Tisch R,. 2011. Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes. Hum Vaccines 7: 27-36.
56. Jones DB, Hunter NR, Duff GW,. 1990. Heat-shock protein 65 as a beta cell antigen of insulin-dependent diabetes. Lancet 336: 583-585. (Pubitemid 20296916)
57. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV,. 1993. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72. (Pubitemid 23345238)
58. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ,. 1992. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 89: 283-292.
59. Keller RJ, Eisenbarth GS, Jackson RA,. 1993. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341: 927-928. (Pubitemid 23109113)
60. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, Hering BJ, Hafler DA,. 2005. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435: 224-228. (Pubitemid 40685950)
61. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, et al. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608. (Pubitemid 41007846)
62. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, et al. 2010. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53: 614-623.
63. Kupila A, Sipila J, Keskinen P, Simell T, Knip M, Pulkki K, Simell O,. 2003. Intranasally administered insulin intended for prevention of type 1 diabetes-a safety study in healthy adults. Diabetes Metab Res Rev 19: 415-420. (Pubitemid 37185383)
64. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z,. 2007. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 23: 286-291. (Pubitemid 46851469)
65. Lernmark A,. 1996. Glutamic acid decarboxylase-gene to antigen to disease. J Intern Med 240: 259-277. (Pubitemid 26388855)
66. Lernmark A, Larsson HE,. 2011. Editorial Comment on type 1 diabetes and antigen-specific immunotherapy. Journal of internal medicine 270: 132-135.
67. Leslie M,. 2011. Immunology. Regulatory T cells get their chance to shine. Science 332: 1020-1021.
68. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, et al. 2008. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359: 1909-1910.
69. Ludvigsson J, Hjorth M, Cheramy M, Axelsson S, Pihl M, Forsander G, Nilsson NO, Samuelsson BO, Wood T, Aman J, et al. 2011. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 54: 634-640.
70. Ma S, Huang Y, Yin Z, Menassa R, Brandle JE, Jevnikar AM,. 2004. Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc Natl Acad Sci USA 101: 5680-5685. (Pubitemid 38481216)
71. Mally MI, Cirulli V, Otonkoski T, Soto G, Hayek A,. 1996. Ontogeny and tissue distribution of human GAD expression. Diabetes 45: 496-501. (Pubitemid 26110256)
72. Mathieu C, Gillard P,. 2011. Arresting type 1 diabetes after diagnosis: GAD is not enough. Lancet 378: 291-292.
73. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M,. 2010. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160: 176-184.
74. Mowat AM,. 1987. The regulation of immune responses to dietary protein antigens. Immunol Today 8: 93-98.
75. Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, Krischer J, Maclaren N,. 1995. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 95: 628-634.
76. Naik RG, Brooks-Worrell BM, Palmer JP,. 2009. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 94: 4635-4644.
77. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, et al. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435: 220-223. (Pubitemid 40685949)
78. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipila JI, Haavisto L, et al. 2008. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372: 1746-1755.
79. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, et al. 2010. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Automimmun 34: 408-415.
80. Ozawa Y, Kasuga A, Nomaguchi H, Maruyama T, Kasatani T, Shimada A, Takei I, Miyazaki J, Saruta T,. 1996. Detection of autoantibodies to the pancreatic islet heat shock protein 60 in insulin-dependent diabetes mellitus. J Automimmun 9: 517-524. (Pubitemid 26273642)
81. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, et al. 2009. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361: 2143-2152.
82. Petersen JS, Bregenholt S, Apostolopolous V, Homann D, Wolfe T, Hughes A, De Jongh K, Wang M, Dyrberg T, Von Herrath MG,. 2003. Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clin Exp Immunol 134: 38-45. (Pubitemid 37186585)
83. Pfleger C, Meierhoff G, Kolb H, Schloot NC,. 2010. Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. J Automimmun 34: 127-135.
84. Pillemer SR,. 2008. Preserving beta cells in type I diabetes mellitus: the role of immunological tolerance. Drug Dev Res 69: 153-157.
85. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, Spera S, Suraci C, Multari G, Cervoni M, et al. 2000. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 43: 1000-1004. (Pubitemid 30655719)
86. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA,. 2009. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58: 652-662.
87. Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D,. 2007. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 23: 292-298. (Pubitemid 46851470)
88. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR,. 2001. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358: 1749-1753. (Pubitemid 33152998)
89. Res PC, Schaar CG, Breedveld FC, van Eden W, van Embden JD, Cohen IR, de Vries RR,. 1988. Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet 2: 478-480.
90. Schloot NC, Meierhoff G, Lengyel C, Vandorfi G, Takacs J, Panczel P, Barkai L, Madacsy L, Oroszlan T, Kovacs P, et al. 2007. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 23: 276-285. (Pubitemid 46851468)
91. Shah SC, Malone JI, Simpson NE,. 1989. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 320: 550-554. (Pubitemid 19070538)
92. Skyler JS,. 2007. Prediction and prevention of type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 81: 768-771. (Pubitemid 46625122)
93. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E,. 2005. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 28: 1068-1076. (Pubitemid 40616615)
94. Soltesz G, Patterson C, Dahlquist G,. 2009. Diabetes in the young: a global perspective. IDF diabetes atlas. 4th ed. Brussels: International Diabetes Federation.
95. Sorenson RL, Garry DG, Brelje TC,. 1991. Structural and functional considerations of GABA in islets of Langerhans. Beta-cells and nerves. Diabetes 40: 1365-1374.
96. Sun JB, Holmgren J, Czerkinsky C,. 1994. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 91: 10795-10799. (Pubitemid 24349571)
97. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, Kaufman DL,. 1996a. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183: 1561-1567. (Pubitemid 26134299)
98. Tian J, Clare-Salzler M, Herschenfeld A, Middleton B, Newman D, Mueller R, Arita S, Evans C, Atkinson MA, Mullen Y, et al. 1996b. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2: 1348-1353.
99. Tiittanen M, Paronen J, Savilahti E, Virtanen SM, Ilonen J, Knip M, Akerblom HK, Vaarala O,. 2006. Dietary insulin as an immunogen and tolerogen. Pediatr Allergy Immunol 17: 538-543. (Pubitemid 44511090)
100. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO,. 1998. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 47: 894-899. (Pubitemid 28255662)
101. Tisch R, Wang B, Serreze DV,. 1999. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 163: 1178-1187. (Pubitemid 29352732)
102. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO,. 1993. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75. (Pubitemid 23345239)
103. van Belle TL, Coppieters KT, von Herrath MG,. 2011. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79-118.
104. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R,. 2009. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32: 2036-2040.
105. Wells HG,. 1911. Studies on the chemistry of anaphylaxis. III. Experiments with isolated proteins, especially those of the hen's egg. J Infect Dis 9: 147-171.
106. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, et al. 2007. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104: 17040-17045. (Pubitemid 350210987)
107. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, et al. 2011. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378: 319-327.
108. Winter WE, Schatz DA,. 2011. Autoimmune markers in diabetes. Clin Chem 57: 168-175.
109. Yang W, Reyes AA, Lan NC,. 1994. Identification of the GABAA receptor subtype mRNA in human pancreatic tissue. FEBS Lett 346: 257-262.
110. + regulatory T cell function via innate TLR2 signaling. J Clin Invest 116: 2022-2032. (Pubitemid 44033326)
111. Zechel MA, Elliott JF, Atkinson MA, Singh B,. 1998. Characterization of novel T-cell epitopes on 65 kDa and 67 kDa glutamic acid decarboxylase relevant in autoimmune responses in NOD mice. J Autoimmun 11: 83-95. (Pubitemid 28080731)
112. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL,. 1991. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88: 10252-10256. (Pubitemid 21915813)
113. Ziegler AG, Hummel M, Schenker M, Bonifacio E,. 1999. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48: 460-468. (Pubitemid 29106857)